TGFB1 and cancer: The efficacy and safety of BR102 demonstrated in preclinical characterization supported its further clinical development for anti-cancer therapy.978 Notably, the bifunctional antibody-ligand traps have inspired the development of chimeric antigen receptor (CAR)-T cells secreting bispecific trap protein, which co-targets PD-1 and TGF-β to enhance anti-tumor efficacy as shown in mouse models.979